Plasma cytokine and soluble receptor signature predicts outcome of patients with classical Hodgkin's lymphoma: A study from the groupe d'Etude des lymphomes de l'Adulte

Journal of Clinical Oncology

Volumn 25, Issue 13, 2007, Pages 1732-1740

  Casasnovas, René Olivier ^a   Mounier, Nicolas ^a   Brice, Pauline ^a   Divine, Marine ^a   Morschhauser, Franck ^a   Gabarre, Jean ^a   Blay, Jean Yves ^a   Voillat, Laurent ^a   Lederlin, Pierre ^a   Stamatoullas, Aspasia ^a   Bienvenu, Jacques ^a   Guiguet, Michel ^a   Intrator, Liliane ^a   Grandjean, Monique ^a   Brière, Josette ^a   Ferme, Christophe ^a   Salles, Gilles ^a  

^a HÔPITAL DU BOCAGE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CD30 ANTIGEN; CYTOKINE; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 10; INTERLEUKIN 6; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR 1; TUMOR NECROSIS FACTOR RECEPTOR 2;

ADOLESCENT; ADULT; AGED; ARTICLE; CANCER CLASSIFICATION; CANCER RELAPSE; CANCER SURVIVAL; CLASSICAL HODGKIN LYMPHOMA; CONTROLLED STUDY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; METASTASIS; PRIORITY JOURNAL; PROGNOSIS; PROTEIN BLOOD LEVEL; SCORING SYSTEM; SYMPTOMATOLOGY; TREATMENT FAILURE; TREATMENT OUTCOME;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CYTOKINES; HODGKIN DISEASE; HUMANS; MIDDLE AGED; MULTIVARIATE ANALYSIS; PROSPECTIVE STUDIES; RECEPTORS, CYTOKINE; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 34249041983     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2006.08.1331     Document Type: Article

References (35)

1. Carde P, Hagenbeek A, Hayat M, et al: Clinical staging versus laparotomy and combined modality with MOPP versus ABVD in early-stage Hodgkin's disease: The H6 twin randomized trials from the European Organization for Research and Treatment of Cancer Lymphoma Cooperative Group. J Clin Oncol 11:2258-2272, 1993
2. Duhmke E, Diehl V, Loeffler M, et al: Randomized trial with early-stage Hodgkin's disease testing 30 Gy vs. 40 Gy extended field radiotherapy alone. Int J Radiat Oncol Biol Phys 36:305-310, 1996
3. Gospodarowicz MK, Sutcliffe SB, Bergsagel DE, et al: Radiation therapy, in clinical stage I and II Hodgkin's disease: The Princess Margaret Hospital Lymphoma Group. Eur J Cancer 28A:1841-1846, 1992
4. Gisselbrecht C, Mounier N, Andre M, et al: How to define intermediate stage in Hodgkin's lymphoma? Eur J Haematol Suppl 111-114, 2005
5. Hasenclever D, Diehl V: A prognostic score for advanced Hodgkin's disease: International Prognostic Factors Project on Advanced Hodgkin's Disease. N Engl J Med 339:1506-1514, 1998
6. Skinnider BF, Mak TW: The role of cytokines in classical Hodgkin lymphoma. Blood 99:4283-4297, 2002
7. Skinnider BF, Elia AJ, Gascoyne RD, et al: lnterleukin 13 and interleukin 13 receptor are frequently expressed by Hodgkin and Reed-Sternberg cells of Hodgkin lymphoma. Blood 97:250-255, 2001
8. Hooper NM, Karran EH, Turner AJ: Membrane protein secretases. Biochem J 321:265-279, 1997 (part 2)
9. Hansen HP, Dietrich S, Kisseleva T, et al: CD30 shedding from Karpas 299 lymphoma cells is mediated by TNF-alpha-converting enzyme. J Immunol 165:6703-6709, 2000
10. Stein H, Delsol G, Pileri S: Classical Hodgkin lymphoma pathology and genetics of tumours of haematopoietic and lymphoid tissues. Lyon, France, IARC Press, 2001, pp 244-253
11. Cheson BD, Horning SJ, Coiffier B, et al: Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas: NCI Sponsored International Working Group. J Clin Oncol 17:1244, 1999
12. Zweig MH, Campbell G: Receiver-operating characteristic (ROC) plots: A fundamental evaluation tool in clinical medicine. Clin Chem 39:561-577, 1993
13. Cox D: Regression model and life tables. Stat Soc B 34:187-220, 1972
14. Akaike H: A new look at the statistical model identification. Automatic Control, IEEE Transactions 19:716-723, 1974
15. Efron B: Bootstrap methods: Another look at the jackknife. Ann Stat 1979:1-26, 1979
16. Zanotti R, Trolese A, Ambrosetti A, et al: Serum levels of soluble CD30 improve International Prognostic Score in predicting the outcome of advanced Hodgkin's lymphoma. Ann Oncol 13:1908-1914, 2002
17. Vener C, Guffanti A, Pomati M, et al: Soluble cytokine levels correlate with the activity and clinical stage of Hodgkin's disease at diagnosis. Leuk Lymphoma 37:333-339, 2000
18. Axdorph U, Sjoberg J, Grimfors G, et al: Biological markers may add to prediction of outcome achieved by the International Prognostic Score in Hodgkin's disease. Ann Oncol 11:1405-1411, 2000
19. Nadali G, Tavecchia L, Zanolin E, et al: Serum level of the soluble form of the CD30 molecule identifies patients with Hodgkin's disease at high risk of unfavorable outcome. Blood 91:3011-3016, 1998
20. Gause A, Pohl C, Tschiersch A, et al: Clinical significance of soluble CD30 antigen in the sera of patients with untreated Hodgkin's disease. Blood 77:1983-1988, 1991
21. Nadali G, Vinante F, Ambrosetti A, et al: Serum levels of soluble CD30 are elevated in the majority of untreated patients with Hodgkin's disease and correlate with clinical features and prognosis. J Clin Oncol 12:793-797, 1994
22. Su CC, Chiu HH, Chang CC, et al: CD30 is involved in inhibition of T-cell proliferation by Hodgkin's Reed-Sternberg cells. Cancer Res 64:2148-2152, 2004
23. Hargreaves PG, Al-Shamkhani A: Soluble CD30 binds to CD153 with high affinity and blocks transmembrane signaling by CD30. Eur J Immunol 32:163-173, 2002
24. Warzocha K, Bienvenu J, Ribeiro P, et al: Plasma levels of tumour necrosis factor and its soluble receptors correlate with clinical features and outcome of Hodgkin's disease patients. Br J Cancer 77:2357-2362, 1998
25. Horie R, Watanabe T, Morishita Y, et al: Ligand-independent signaling by overexpressed CD30 drives NF-kappaB activation in Hodgkin-Reed-Sternberg cells. Oncogene 21:2493-2503, 2002
26. Hinz M, Lemke P, Anagnostopoulos I, et al: Nuclear factor kappaB-dependent gene expression profiling of Hodgkin's disease tumor cells, pathogenetic significance, and link to constitutive signal transducer and activator of transcription 5a activity. J Exp Med 196:605-617, 2002
27. Cozen W, Gill PS, Ingles SA, et al: IL-6 levels and genotype are associated with risk of young adult Hodgkin lymphoma. Blood 103:3216-3221, 2004
28. Seymour JF, Talpaz M, Hagemeister FB, et al: Clinical correlates of elevated serum levels of interleukin 6 in patients with untreated Hodgkin's disease. Am J Med 102:21-28, 1997
29. Gruss HJ, Dolken G, Brach MA, et al: High concentrations of the interleukin-1 receptor antagonist in serum of patients with Hodgkin's disease. Lancet 340:968, 1992
30. Gabay C, Porter B, Guenette D, et al: Interleukin-4 (IL-4) and IL-13 enhance the effect of IL-1 beta on production of IL-1 receptor antagonist by human primary hepatocytes and hepatoma HepG2 cells: Differential effect on C-reactive protein production. Blood 93:1299-1307, 1999
31. Crepaldi L, Silveri L, Calzetti F, et al: Molecular basis of the synergistic production of IL-1
32. receptor antagonist by human neutrophils stimulated with IL-4 and IL-10. Int Immunol 14:1145-1153, 2002
33. Sarris AH, Kliche KO, Pethambaram P, et al: Interleukin-10 levels are often elevated in serum of adults with Hodgkin's disease and are associated with inferior failure-free survival. Ann Oncol 10:433-440, 1999
34. Vassilakopoulos TP, Nadali G, Angelopoulou MK, et al: Serum interleukin-10 levels are an independent prognostic factor for patients with Hodgkin's lymphoma. Haematologica 86:274-281, 2001
35. Visco C, Vassilakopoulos TP, Kliche KO, et al: Elevated serum levels of IL-10 are associated with inferior progression-free survival in patients with Hodgkin's disease treated with radiotherapy. Leuk Lymphoma 45:2085-2092, 2004